About Urogen Pharma (NASDAQ:URGN)
Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidates include Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). Its platform technologies include: RTGel and Immunotherapy.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:URGN
- CUSIP: N/A
- Web: www.urogen.com
- Market Cap: $355.67 million
- Outstanding Shares: 13,009,000
- 50 Day Moving Avg: $29.80
- 200 Day Moving Avg: $21.41
- 52 Week Range: $13.01 - $33.77
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -9.46
- P/E Growth: 0.00
- Annual Revenue: $17.55 million
- Price / Sales: 20.27
- Book Value: $5.69 per share
- Price / Book: 4.80
- Current Ratio: 15.79%
- Quick Ratio: 15.71%
- Average Volume: 51,226 shs.
- Short Ratio: 0.54
Frequently Asked Questions for Urogen Pharma (NASDAQ:URGN)
What is Urogen Pharma's stock symbol?
Urogen Pharma trades on the NASDAQ under the ticker symbol "URGN."
When will Urogen Pharma make its next earnings announcement?
Where is Urogen Pharma's stock going? Where will Urogen Pharma's stock price be in 2017?
4 brokerages have issued 12-month target prices for Urogen Pharma's shares. Their forecasts range from $25.00 to $37.00. On average, they anticipate Urogen Pharma's share price to reach $31.33 in the next twelve months. View Analyst Ratings for Urogen Pharma.
Who are some of Urogen Pharma's key competitors?
Some companies that are related to Urogen Pharma include Vanda Pharmaceuticals (VNDA), PTC Therapeutics (PTCT), Flexion Therapeutics (FLXN), Audentes Therapeutics (BOLD), Aclaris Therapeutics (ACRS), Intra-Cellular Therapies (ITCI), Coherus BioSciences (CHRS), Dova Pharmaceuticals (DOVA), Aduro Biotech (ADRO), Adaptimmune Therapeutics PLC (ADAP), G1 Therapeutics (GTHX), Paratek Pharmaceuticals (PRTK), MacroGenics (MGNX), Synergy Pharmaceuticals (SGYP), Axovant Sciences Ltd (AXON), Madrigal Pharmaceuticals (MDGL), Calithera Biosciences (CALA) and Achaogen (AKAO).
Who are Urogen Pharma's key executives?
Urogen Pharma's management team includes the folowing people:
- Arie S. Belldegrun, Chairman of the Board
- Ron Bentsur, Chief Executive Officer, Director
- Gary S. Titus, Chief Financial Officer
- Gil Hakim, President - Israeli Operation
- Chaim Hurvitz, Director
- Ran Nussbaum, Director
- Kathryn E. Falberg, Independent Director
- Stuart Holden M.D., Independent Director
- Pini Orbach Ph.D., Independent Director
When did Urogen Pharma IPO?
(URGN) raised $46 million in an initial public offering on Thursday, May 4th 2017. The company issued 3,500,000 shares at $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.
When does the company's lock-up period expire?
Urogen Pharma's lock-up period expires on Tuesday, October 31st. Urogen Pharma had issued 4,473,373 shares in its initial public offering on May 4th. The total size of the offering was $58,153,849 based on an initial share price of $13.00. After the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.
Who owns Urogen Pharma stock?
Who bought Urogen Pharma stock? Who is buying Urogen Pharma stock?
How do I buy Urogen Pharma stock?
Shares of Urogen Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Urogen Pharma's stock price today?
MarketBeat Community Rating for Urogen Pharma (NASDAQ URGN)MarketBeat's community ratings are surveys of what our community members think about Urogen Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Urogen Pharma stock can currently be purchased for approximately $27.34.
Consensus Ratings for Urogen Pharma (NASDAQ:URGN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||4 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$31.33 (14.61% upside)|Consensus Price Target History for Urogen Pharma (NASDAQ:URGN)
Analysts' Ratings History for Urogen Pharma (NASDAQ:URGN)
(Data available from 10/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/9/2017||Jefferies Group LLC||Boost Price Target||Buy||$27.00 -> $37.00||N/A|
|8/14/2017||Oppenheimer Holdings, Inc.||Set Price Target||Buy||$32.00||High|
|5/30/2017||Raymond James Financial, Inc.||Initiated Coverage||Outperform -> Outperform||$25.00||High|
|5/30/2017||Cowen and Company||Initiated Coverage||Outperform||High|
Earnings History for Urogen Pharma (NASDAQ:URGN)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Urogen Pharma (NASDAQ:URGN)
2017 EPS Consensus Estimate: ($3.54)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Urogen Pharma (NASDAQ:URGN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Urogen Pharma (NASDAQ:URGN)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Urogen Pharma (NASDAQ:URGN)
Latest Headlines for Urogen Pharma (NASDAQ:URGN)
Loading headlines, please wait.
Urogen Pharma (URGN) Chart for Monday, October, 23, 2017